igue , ▁clin ical ▁de pression , ▁br ady card ia , ▁or ▁imp ot ence . ▁However , ▁according ▁to ▁the ▁F DA ▁ ▁F DA ▁warning ▁letter ▁about ▁advert ising ▁claims ▁In ▁late ▁August ▁ 2 0 0 8 , ▁the ▁F DA ▁issued ▁a ▁Warning ▁Let ter ▁to ▁Forest ▁Labor ator ies ▁cit ing ▁ex agger ated ▁and ▁mis leading ▁claims ▁in ▁their ▁launch ▁journal ▁ad , ▁in ▁particular ▁over ▁claims ▁of ▁superior ity ▁and ▁novel ty ▁of ▁action . ▁ ▁History ▁My lan ▁Labor ator ies ▁lic ensed ▁the ▁U . S . ▁and ▁Canadian ▁rights ▁to ▁ne b iv ol ol ▁from ▁J ans sen ▁Ph arma ce ut ica ▁N . V . ▁in ▁ 2 0 0 1 . ▁Neb iv ol ol ▁is ▁already ▁registered ▁and ▁successfully ▁market ed ▁in ▁more ▁than ▁ 5 0 ▁countries , ▁including ▁the ▁United ▁States ▁where ▁it ▁is ▁market ed ▁under ▁the ▁brand ▁name ▁B yst ol ic ▁from ▁My lan ▁Labor ator ies ▁and ▁Forest ▁Labor ator ies . ▁Neb iv ol ol ▁is ▁manufact ured ▁by ▁Forest ▁Labor ator ies . ▁ ▁In ▁India , ▁ne b iv ol ol ▁is ▁available ▁as ▁Neb ula ▁( Z yd us ▁Health care ▁Ltd ), ▁Neb iz ok ▁( Er is ▁life - sci ences ), ▁Neb icip ▁( C ip la ▁l td ), ▁Neb il ong ▁( M icro ▁L abs ), ▁Neb ist ar ▁( L up in ▁l td ), ▁Neb ic ard ▁( T